[Skip to Content]
[Skip to Content Landing]
Views 897
Citations 0
Comment & Response
June 10, 2020

Brain Volume Changes Under Treatment With Antipsychotics

Author Affiliations
  • 1Third Department of Psychiatry, Faculty of Medicine, Aristotle University of Thessaloniki School of Health Sciences, Pylaia, Thessaloniki, Greece
JAMA Psychiatry. Published online June 10, 2020. doi:10.1001/jamapsychiatry.2020.1358

To the Editor In the secondary analysis of a double-blind discontinuation randomized clinical trial of adjunctive olanzapine vs placebo on top of sertraline, Voineskos et al1 reported that antipsychotic medication reduces brain gray matter volume and where alternatives are present, antipsychotics should be avoided.

In fact, there are no alternatives with solidly proven efficacy, and phrases like this could be misleading especially because more patients under the discontinuation arm manifested a relapse although they had previously achieved sustained remission. The complete picture of the results (4 groups defined by treatment and relapse status) seems more complex, but the authors do not report them in sufficient detail. Among patients in relapse, those in the placebo group had worse findings compared with those in the olanzapine group, which might mean olanzapine exerted a neuroprotective effect independent of its antipsychotic effect. What is puzzling is that patients in the olanzapine group performed better when there was a significant brain gray matter volume loss. This raises the question whether antipsychotic-induced cortical thickness reduction is related to treatment response and whether such a correlation reflects a causal relationship and is not spurious. Gray matter loss is not always a bad thing; it transiently happens also during normal conditions, eg, during pregnancy.2

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×